Your browser doesn't support javascript.
loading
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium.
Shimizu, Toshio; Kim, Dong-Wan; Loong, Herbert H; Lin, Chia-Chi; Ng, Matthew Ch; Yamamoto, Noboru; Ma, Brigette; Tan, Daniel Sw.
Afiliação
  • Shimizu T; Early Phase 1 Drug Development Service, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Kim DW; Department of Internal Medicine, Clinical Trials Center, Seoul National University Hospital, Seoul, South Korea.
  • Loong HH; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Lin CC; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Ng MC; Phase 1 Center, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Yamamoto N; Experimental Cancer Therapeutics Unit, Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Ma B; Early Phase 1 Drug Development Service, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Tan DS; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong SAR, China.
Asia Pac J Clin Oncol ; 17(4): 388-395, 2021 Aug.
Article em En | MEDLINE | ID: mdl-33502085
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / COVID-19 / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / COVID-19 / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article